Clinical Trials Begin in Sweden for First Bundibugyo Ebola Vaccine

Swedish researchers have initiated clinical trials for a groundbreaking Bundibugyo Ebola vaccine, marking a significant milestone as the first potential vaccine for this Ebola strain to reach human testing stages. The study involves 50 healthy adult volunteers aged between 18 and 55 years. Participants will receive the vaccine and be monitored for one year, although researchers anticipate collecting key data on the vaccine's effectiveness within just a few weeks.

This vaccine builds upon previous research by Oxford University and AstraZeneca, which notably contributed to the development of the COVID-19 vaccine. The urgency for this trial is underscored by a severe Ebola outbreak currently ongoing in Kongo-Kinshasa that has caused nearly 900 deaths since May 2026.

The trial reflects advances in Swedish medical research, providing hope for a targeted vaccine response to the Bundibugyo strain of Ebola, complementing efforts worldwide to control the deadly virus.